Ragweed pollen allergens: description and prospects for the development of new highly effective allergy vaccines



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Ragweed pollen allergy is widespread in the southern regions of the Russian Federation, where it accounts for up to 30% of all allergy cases, representing an important public health problem. Drugs of various pharmacological groups used for the treatment of ragweed pollen allergy affect only the symptoms but not the cause of allergy. Existing pathogenetic therapy (allergen-specific immunotherapy with allergy vaccines based on water-salt extracts) requires long courses and can cause significant side effects. The development of more effective allergy vaccines requires the study of the structures of ragweed pollen allergens and the identification of their IgE epitopes. Based on these epitopes, new highly effective allergy vaccines can be developed using recombinant technologies that will lack the disadvantages of water-salt extracts and will also have the ability to enhance the induction of protective IgG.

This review is focused on the epidemiology of ragweed pollen allergy, as well as the latest approaches to the development of allergy vaccines and the study of the structure of ragweed pollen allergens, and the information presented is relevant for the development of new promising highly effective allergy vaccines for allergen-specific immunotherapy of ragweed pollen allergy.

Full Text

Additional information

Funding source. The work and publication were supported by the Russian Science Foundation grant No. № 24-15-00206 (https://www.rscf.ru/project/24-15-00206/)

Competing interests. The authors declare that they have no competing interests.

Authors’ contribution. All authors made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published and agree to be accountable for all aspects of the work. A.A. Shatilov, A.V. Shatilova, A.A. Asanbaeva, M.O. Babikhina ― collection and analysis of literary sources, preparation and writing of the article; I.P. Shilovskiy, S.M.Andreev, V.V. Smirnov, E.V. Nazarova,  G.B. Pasikhov, M.V. Popova, P.A. Strueva, O.G. Elisyutina, O.P. Ukhanova, D.A. Kudlay ― collection and analysis of literary sources, M.R. Khaitov ― writing the text and editing the article.

×

About the authors

Artem A. Shatilov

National Research Center – Institute of Immunology Federal Medical-Biological Agency

Email: aa.shatilov@nrcii.ru
ORCID iD: 0000-0002-4675-8074
SPIN-code: 6768-5796

 Researcher 

Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia.

Anastasiia V. Shatilova

National Research Center – Institute of Immunology Federal Medical-Biological Agency

Author for correspondence.
Email: av.timofeeva@nrcii.ru
ORCID iD: 0000-0003-3780-2878
SPIN-code: 1988-1536

 Researcher 

Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia.

Aizirek A. Asanbaeva

National Research Center – Institute of Immunology Federal Medical-Biological Agency; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: asanbaeva-a42@yandex.ru
ORCID iD: 0009-0000-2395-6468

Assistant

Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia; Trubeckaia ul., 8 stroenie 2, 119048 Moscow.

Marina O. Babikhina

National Research Center – Institute of Immunology Federal Medical-Biological Agency

Email: marinababihina@yandex.ru
ORCID iD: 0009-0000-5935-1647
SPIN-code: 4621-0268

Assistant

Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia.

Igor P. Shilovskii

National Research Center – Institute of Immunology Federal Medical-Biological Agency

Email: ip.shilovsky@nrcii.ru
ORCID iD: 0000-0001-5343-4230
SPIN-code: 6008-7323

доктор биологических наук, зам. директора по науке и инновациям

Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia.

Sergei M. Andreev

National Research Center – Institute of Immunology Federal Medical-Biological Agency

Email: andsergej@yandex.ru
ORCID iD: 0000-0001-8297-579X
SPIN-code: 2542-5260

PhD

Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia.

Valerii V. Smirnov

National Research Center – Institute of Immunology Federal Medical-Biological Agency; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: vall@mail.mipt.ru
ORCID iD: 0000-0002-8232-6682
SPIN-code: 4171-3871

Dr.Sci., Assistant professor

Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia; Trubeckaia ul., 8 stroenie 2, 119048 Moscow.

Evgeniya V. Nazarova

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ev.nazarova@nrcii.ru
ORCID iD: 0000-0003-0380-6205
SPIN-code: 4788-7407

MD, Cand. Sci. (Med.)

Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia.

George B. Pasikhov

National Research Center – Institute of Immunology Federal Medical-Biological Agency

Email: george.pasikhov@yandex.ru
ORCID iD: 0009-0007-8916-3322
SPIN-code: 6283-5320
Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia.

Maiia V. Popova

National Research Center – Institute of Immunology Federal Medical-Biological Agency

Email: mayhemly@mail.ru
ORCID iD: 0000-0002-3671-780X
Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia.

Polina A. Strueva

National Research Center – Institute of Immunology Federal Medical-Biological Agency

Email: polly.strueva@yandex.ru
Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia.

Olga G. Elisyutina

National Research Center – Institute of Immunology Federal Medical-Biological Agency

Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-code: 9567-1894

MD, Dr. Sci. (Med.)

Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia.

Olga P. Ukhanova

Federal State Budgetary Educational Institution of Higher Education "Stavropol State Medical University" of the Ministry of Health of the Russian Federation

Email: uhanova_1976@mail.ru
ORCID iD: 0000-0002-7247-0621
SPIN-code: 8287-2891

MD, Dr. Sci. (Med.), Professor

Россия, Stavropol

Dmitry A. Kudlay

National Research Center – Institute of Immunology Federal Medical-Biological Agency; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: D624254@gmail.com
ORCID iD: 0000-0003-1878-4467
SPIN-code: 4129-7880

MD, Dr. Sci. (Med.)

Россия, 24 Kashirskoe Shosse, 115522 Moscow, Russia; Trubeckaia ul., 8 stroenie 2, 119048 Moscow.

Musa R. Khaitov

National Research Center – Institute of Immunology Federal Medical-Biological Agency; Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation

Email: mr.khaitov@nrcii.ru
ORCID iD: 0000-0003-4961-9640
SPIN-code: 3199-9803

MD, Dr. Sci. (Med.), Professor, Corresponding member of the Russian Academy of Sciences

Россия, 24 Kashirskoe Shosse, 115522 Moscow; Moscow

References

  1. Dierick BJH, van der Molen T, Flokstra-de Blok BMJ, Muraro A, Postma MJ, Kocks JWH, et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Rev Pharmacoecon Outcomes Res. 2020;20(5):437-453. doi: 10.1080/14737167.2020.1819793.
  2. Akdis CA, Agache I, editors. Global Atlas of Allergy [Internet]. Zurich: EAACI; 2014. Available from: https://hub.eaaci.org/education_books/global-atlas-of-allergy/
  3. Astafieva NG, Baranov AA, Vishneva EA, Daihes NA, Zhestkov AV, Ilina NI, et al. Allergic rhinitis. Russian Journal of Allergy. 2022;19(1):100-141. (In Russ). doi: 10.36691/RJA1524
  4. Kurbacheva OM, Pavlova KS, Kozulina IE. Allergen-specific immunotherapy: history, methods and new options. Meditsinskiy sovet Carnes J, Gallego MT, Moya R, Iraola V. Allergoids for Allergy Treatment. Recent Pat Inflamm Allergy Drug Discov. 2018;12(2):110-119. doi: 10.2174/1872213X12666180221155908.
  5. Compalati E, Incorvaia C, Cavaliere C, Masieri S, Gargiulo A, Mistrello G, et al. The role of allergoids in allergen immunotherapy: from injective to sublingual route. Eur Ann Allergy Clin Immunol. 2020;52(5):195-204. doi: 10.23822/Khaitov M, Shilovskiy I, Valenta R, Weber M, Korneev A, Tulaeva I, et al. Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy. Allergy. 2024;79(4):1001-1017. doi: 10.1111/all.15919.
  6. Zhernov Y, Curin M, Khaitov M, Karaulov A, Valenta R. Recombinant allergens for immunotherapy: state of the art. Curr Opin Allergy Clin Immunol. 2019; 19 (4): 402–14. doi: https://doi.org/10.1097/ACI.0000000000000536
  7. Niederberger V, Neubauer A, Gevaert P, Zidarn M, Worm M, Aberer W, et al. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. J Allergy Clin Immunol. 2018;142(2):497-509.e9. doi: 10.1016/j.jaci.2017.09.052.
  8. Bullock JM, Chapman D, Schafer S, Roy D, Girardello M, Haynes T, et al. Assessing and controlling the spread and the effects of common ragweed in Europe. Final report: ENV.B2/ETU/2010/0037 [Internet]. 2011:456. Available from: https://op.europa.eu/en/publication-detail/-/publication/4a633a9e-5da6-404b-8082-b0e4be4b39f1
  9. Gergen PJ, Arbes SJ Jr, Calatroni A, Mitchell HE, Zeldin DC. Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2009;124(3):447-453. doi: 10.1016/j.jaci.2009.06.011.
  10. Burbach GJ, Heinzerling LM, Röhnelt C, Bergmann KC, Behrendt H, Zuberbier T; GA(2)LEN study. Ragweed sensitization in Europe - GA(2)LEN study suggests increasing prevalence. Allergy. 2009;64(4):664-5. doi: 10.1111/j.1398-9995.2009.01975.x.
  11. Sommer J, Smith M, Sikoparija B, Kasprzyk I, Myszkowska D, Grewling L, et al. Risk of exposure to airborne Ambrosia pollen from local and distant sources in Europe - an example from Denmark. Ann Agric Environ Med. 2015;22(4):625-631. doi: 10.5604/12321966.1185764.
  12. Macharadze DSh. Ambrosia Allergy. Diagnosis And Treatment Characteristics. Meditsinskiy opponent=Medical opponent. 2019; 2(6): 48–55. (In Russ).
  13. May JR, Dolen WK. Management of Allergic Rhinitis: A Review for the Community Pharmacist. Clin Ther. 2017;39(12):2410-2419. doi: 10.1016/j.clinthera.2017.10.006.
  14. Pavlova KS, Timoshenko DO, Gushchin IS, Kurbacheva OM. Allergen immunotherapy: on the path to achieving immune tolerance. Immunologiya. 2024; 45 (1): 82–90. (in Russ.) doi: https://doi.org/10.33029/1816-2134-2024-45-1-82-90
  15. Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir Med. 2009;103(6):800-812. doi: 10.1016/j.rmed.2009.01.008.
  16. Ukhanova OP, Ebzeeva II. Treatment of ragweed pollinosis using sublingual allergens. Russian Journal of Allergy. 2019;16(4):17–23. (In Russ). doi: 10.36691/RAJ.2020.16.4.002
  17. Dorofeeva Y, Shilovskiy I, Tulaeva I, Focke-Tejkl M, Flicker S, Kudlay D, et al. Past, present, and future of allergen immunotherapy vaccines. Allergy. 2020;76(1):131–149. doi: 10.1111/all.14300.
  18. Kurbacheva OM, Pavlova KS. Allergen-specific immunotherapy: modern possibilities. Asthma and allergy. 2015; (3): 16–20. (in Russ.)
  19. Valenta R, Kraft D. Recombinant allergen molecules: Tools to study effector cell activation. Immunol Rev. 2001;179(1):119–127. doi: 10.1034/j.1600-065x.2001.790112.x.
  20. Gieras A, Focke-Tejkl M, Ball T, Verdino P, Hartl A, Thalhamer J, et al. Molecular determinants of allergen-induced effector cell degranulation. J Allergy Clin Immunol. 2007;119(2):384-390. doi: 10.1016/j.jaci.2006.09.034.
  21. Brazhnikov G, Smolnikov E, Litovkina A, Jiang T, Shatilov A, Tulaeva I, et al. Natural human Bet v 1‐specific IgG antibodies recognize non‐conformational epitopes whereas IgE reacts with conformational epitopes. Allergy. 2023;78(12):3136–3153. doi: 10.1111/all.15865.
  22. Schulmeister U, Hochwallner H, Swoboda I, Focke-Tejkl M, Geller B, Nystrand M, et al. Cloning, expression, and mapping of allergenic determinants of alphaS1-casein, a major cow's milk allergen. J Immunol. 2009;182(11):7019-7029. doi: 10.4049/jimmunol.0712366
  23. Tulaeva I., Kratzer B., Campana R., Curin M., van Hage M., Karsonova A., et al. Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? Front. Immunol. 2020; 11: 1368. doi: https://doi.org/10.3389/fimmu.2020.01368
  24. Elisyutina OG, Shershakova NN, Smirnov VV, Shilovskiy IP, Korneev AV, Poroshina AS, et al. New approaches to allergen-specific immunotherapy (ASIT): development of a recombinant vaccine against birch pollen allergy. Immunologiya. 2022;43(6):621–631. (In Russ). doi: 10.33029/0206-4952-2022-42-6-621-631.
  25. Linhart B, Narayanan M, Focke-Tejkl M, Wrba F, Vrtala S, Valenta R. Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Clin Exp Allergy. 2014;44(2):278-287. doi: 10.1111/cea.12216.
  26. Valenta R, Karaulov A, Niederberger V, Zhernov Y, Elisyutina O, Campana R, et al. Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? J. Allergy Clin. Immunol. Pract. 2018; 6 (6): 1845–1855.e2. doi: https://doi.org/10.1016/j.jaip.2018.08.032
  27. Ferreira F, Bohle B, Jahn-Schmid B, Wopfner N, Schmidt G, Ebner C, inventors; Biomay AG, assignee. Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof. European patent EP 1958645A1. 2007 Feb 13.
  28. Nandy A, Augustin S, Wald M, Pump L, Hermann A, Treder S, et al. Recombinant Major Ragweed Allergen Amb a 1: Physicochemical Characterization and Immunologic Comparison of Five Recombinant Ragweed Isoallergens Amb a 1.01 to Amb a 1.05. J Allergy Clin Immunol. 2013;131(2):AB16. doi: 10.1016/j.jaci.2012.12.736.
  29. Bernstein DI, Segall N, Nayak A, Casale T, Korenblatt P, Martins E. Safety and Efficacy of the Novel Vaccine TOLAMBA ™ in Ragweed Allergic Adults, a Dose Finding Study. J Allergy Clin Immunol. 2007;119(1):S78–S79. doi: 10.1016/j.jaci.2006.11.332.
  30. Wopfner N, Jahn-Schmid B, Schmidt G, Christ T, Hubinger G, Briza P, et al. The alpha and beta subchain of Amb a 1, the major ragweed-pollen allergen show divergent reactivity at the IgE and T-cell level. Mol Immunol. 2009;46(10):2090-2097. doi: 10.1016/j.molimm.2009.02.005.
  31. Wolf M, Twaroch TE, Huber S, Reithofer M, Steiner M, Aglas L, et al. Amb a 1 isoforms: Unequal siblings with distinct immunological features. Allergy. 2017;72(12):1874-1882. doi: 10.1111/all.13196.
  32. Zahirović A, Štrukelj B, Korošec P, Lunder M. Epitope Mapping of Major Ragweed Allergen Amb a 1. Acta Chim Slov. 2019 Feb;66(1):37-44. doi: 10.17344/acsi.2018.4516.
  33. Jahn-Schmid B, Wopfner N, Hubinger G, Asero R, Ebner C, Ferreira F, et al. The T-cell response to Amb a 1 is characterized by 3 dominant epitopes and multiple MHC restriction elements. J Allergy Clin Immunol. 2010;126(5):1068-1071, 1071.e1-2. doi: 10.1016/j.jaci.2010.05.038.
  34. Bouley J, Groeme R, Le Mignon M, Jain K, Chabre H, Bordas-Le Floch V, et al. Identification of the cysteine protease Amb a 11 as a novel major allergen from short ragweed. J Allergy Clin Immunol. 2015;136(4):1055-1064. doi: 10.1016/j.jaci.2015.03.001.
  35. Tamaș TP, Buzan MR, Zbircea LE, Cotarcă MD, Grijincu M, Păunescu V, et al. Ragweed Major Allergen Amb a 11 Recombinant Production and Clinical Implications. Biomolecules. 2023;13(1):182. doi: 10.3390/biom13010182.
  36. Moten D, Kolchakova D, Todorov K, Mladenova T, Dzhambazov B. Design of an Epitope-Based Peptide Vaccine Against the Major Allergen Amb a 11 Using Immunoinformatic Approaches. Protein J. 2022;41(2):315-326. doi: 10.1007/s10930-022-10050-z.
  37. Groeme R, Airouche S, Kopecny D, Jaekel J, Savko M, Berjont N, et al. Structural and Functional Characterization of the Major Allergen Amb a 11 from Short Ragweed Pollen. J Biol Chem. 2016;291(25):13076-87. doi: 10.1074/jbc.M115.702001.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media,



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies